- Service Name
REGENXBIO
- Industry
Biotechnology, Gene Therapy, Therapeutics, Gene-Based Treatments
- Main Value Proposition
REGENXBIO offers innovative gene therapy solutions that have the potential to provide curative treatments for both common and rare diseases.
- Description
REGENXBIO is a leading clinical-stage biotechnology company focused on developing gene therapy products using its NAV® Technology Platform. The company aims to improve lives through innovative one-time treatments for various diseases.
- Key Features
NAV® Technology Platform; 100+ Novel AAV vectors; Robust Clinical Programs; In-house commercial-ready manufacturing
- Use Cases
REGENXBIO's therapies are particularly valuable for patients suffering from retinal diseases, Duchenne muscular dystrophy, and MPS II (Hunter Syndrome).
- Competitive advantages
Extensive experience in gene therapy development; In-house manufacturing capabilities ensuring quality control; A diverse pipeline targeting multiple therapeutic areas
- Strengths
The company has a strong focus on innovation, a robust pipeline of clinical programs, and a commitment to improving patient outcomes through gene therapy.
- Positioning
REGENXBIO positions itself as a leader in the gene therapy space, emphasizing its pioneering technology and commitment to patient care.
- Audience
The primary target users include patients with genetic disorders, their families, and healthcare providers looking for advanced treatment options.
- CTA
Learn More
- Tags
Gene Therapy
AAV Vectors
Biotechnology
Clinical Programs
- Tagline
Pioneers In Gene Therapy
- Tone of Voice
Innovative, compassionate, professional
- Differentiation
REGENXBIO stands out in the market due to its proprietary NAV® Technology Platform, which enables the development of a wide range of gene therapy products with a focus on safety and efficacy.
- Brand Positioning
The brand is identified as innovative and patient-focused, with a strong emphasis on scientific advancement and community impact.
- Founded
2009-01-01
- Founders
James Brown
James M. Wilson
Kenneth T. Mills